Mitochondrial dysfunction

Mitochondrial dysfunction is the seventh of the twelve hallmarks of aging, and one of the most connected — it both feeds and is fed by genomic instability, senescence, and inflammation. Mitochondria are tiny compartments inside nearly every cell that burn fuel and oxygen to make adenosine triphosphate (ATP), the molecule that powers almost everything a cell does. They are far more than batteries, though: they buffer calcium, decide when a damaged cell should die, and manage the production of reactive oxygen species (ROS) — the unstable, oxygen-containing by-products of energy generation that damage whatever they touch.^[1] With age, the systems that keep this machinery in good repair break down, dysfunctional mitochondria pile up, and the consequences ripple out across the whole body.^[2]

How confident should you be

Descriptive — Strong. Intervention — Moderate.

That mitochondria decay with age, that the decay is mechanistically well characterised, and that it links outward to inflammation and frailty are all settled. The intervention side is stronger here than for most hallmarks — exercise reliably and measurably improves mitochondrial function in humans, which is more than can be said for the levers aimed at genomic instability or proteostasis — but it stops short of proof that improving mitochondria extends life. There is no human lifespan data for any of it, the muscle–brain result that anchors the clinical case is observational, and every supplement in this space has either missed its primary endpoint or never had one tested. The lifestyle levers are the real content of this page; the pills are a footnote to them.

Why mitochondria fail with age

Strong for the mitochondrial-DNA damage, which is mapped in aging human tissue; Moderate for the quality-control decline below, which rests largely on cell and animal work.

Mitochondria carry their own small loop of DNA, a relic of their ancient origin as free-living bacteria, and that DNA is unusually exposed. Unlike the genome in the nucleus, mitochondrial DNA has no protective protein packaging, sits right next to the ROS-spewing energy machinery, and has only basic repair tools — so it accumulates mutations and deletions faster, and these have been mapped in aging human brain, heart, gut, and muscle.^[3]

The cell's defence is a constant quality-control cycle that keeps the mitochondrial pool healthy, and aging degrades every part of it.^[4] Mitochondria turn over every couple of weeks through three coordinated processes:

• Biogenesis — building new mitochondria, driven by a master switch called PGC-1α (the same switch endurance exercise flips on).
• Mitophagy — selectively digesting worn-out mitochondria; a sensor system tags any unit that loses its electrical charge for recycling.
• Fission and fusion — mitochondria constantly split apart and merge, which lets the network quarantine a damaged segment and dilute scattered mutations.

In youth this cycle keeps the network efficient. With age, the balance tips: clearance slows while damaged units pile up, the network fragments, and tissue fills with swollen, inefficient mitochondria that make less ATP and leak more ROS — a self-reinforcing decline.^[5]

From leaky mitochondria to whole-body inflammation

Strong for the mechanism; Moderate for its weight in human aging. The pathway is well characterised in cells and animals; how much of human inflammaging runs through it is not quantified.

The most important recent insight is how a local energy problem becomes a systemic one — and it runs through the same cytosolic-DNA alarm that connects genomic instability to aging. Because mitochondrial DNA still resembles bacterial DNA, the cell treats it as a threat if it ends up in the wrong place. When a damaged mitochondrion's membrane ruptures, its DNA spills into the cytoplasm, where the cGAS-STING sensor — the cell's burglar alarm for misplaced DNA — mistakes it for a virus and switches on a powerful inflammatory and antiviral program.^[6]

A brief burst of this is useful housekeeping. The problem is chronic, low-grade activation that never resolves — an "inflammatory clock" that translates accumulated organelle damage into the persistent, sterile inflammation of inflammaging.^[7] In senescent cells, sustained cGAS-STING signalling pours out the inflammatory secretions (the senescence-associated secretory phenotype) that damage neighbouring tissue.^[8] This is the mechanistic bridge that makes failing mitochondria a driver of body-wide aging rather than just a per-cell energy shortfall.

The muscle–brain axis: how mitochondria show up as frailty and dementia

Weak — observational. One prospective cohort plus a small, confounded cross-sectional comparison. It establishes that muscle mitochondrial function predicts cognitive decline, not that improving it prevents any.

Because some tissues are far more energy-hungry than others, mitochondrial decline tends to surface first where the demand is highest — skeletal muscle and the brain.

In muscle, failing quality control is a direct driver of sarcopenia (age-related muscle loss) and physical frailty: less mass, weaker grip, slower walking.^[9] Strikingly, muscle mitochondrial health also tracks the brain. In the Baltimore Longitudinal Study of Aging, mitochondrial function in the thigh muscle — measured non-invasively by magnetic-resonance spectroscopy — predicted what happened in the brain. Participants whose muscle mitochondria scored one standard deviation better than the cohort average went on to develop mild cognitive impairment or dementia at roughly half the rate of the rest — a 52% lower hazard per standard deviation — and had about 59% lower odds, again per standard deviation, of a positive amyloid brain scan.^[10] Read it as an association: people with better muscle mitochondria differ from those without in many ways, and no trial has tested whether improving the muscle measure changes the brain outcome. People with early mild cognitive impairment also show measurable differences in muscle mitochondrial respiratory capacity, underscoring that this is a systemic, not purely neurological, problem — though that comparison rests on only 50 people, and the effect was entangled with whether participants were taking the Alzheimer's drug donepezil.^[11]

The same energy failure appears in the post-viral fatigue syndromes. In myalgic encephalomyelitis/chronic fatigue syndrome and long-COVID, a stress-induced protein jams the assembly of the energy machinery, cutting ATP output — a molecular correlate of the exhaustion, post-exertional crashes, and "brain fog" that define these conditions.^[12] The broader association between mitochondrial dysfunction and chronic fatigue long predates COVID.^[13]

Mitohormesis: a little stress is the point

Moderate. The principle is well established in cells and animals; the dose–response boundaries in humans are not mapped.

Here is the reframe that organises everything practical about this hallmark. The old "free-radical theory" cast all mitochondrial stress as damage to be minimised. The modern picture is mitohormesis: while high, chronic mitochondrial stress is destructive, a brief, controlled dose of stress triggers an adaptive overcompensation — the cell clears damaged mitochondria, builds new ones, and ends up more resilient than before.^[14] Whether mitochondrial change is harmful or protective depends entirely on the dose.^[15]

This has a counterintuitive practical consequence that is worth stating plainly, because it inverts a generation of supplement marketing. High-dose antioxidant supplements do not slow aging, and taken around training they can make it work less well. The transient burst of reactive oxygen species that exercise produces is not a side effect to be mopped up — it is the signal that tells the cell to build more and better mitochondria. Blunt the signal with large doses of isolated antioxidants and you blunt part of the adaptation you trained for.^[16] Antioxidants in food, at food doses, are a different matter; the problem is the concentrated pill taken alongside the very stressor it cancels.

So the most effective mitochondrial interventions are not pills but hormetic stressors — exercise, fasting, heat, and cold each impose exactly the kind of transient, survivable stress that drives renewal.

What actually helps — the hormetic levers

Moderate for exercise and fasting; Weak for cold and sleep, where the mitochondrial evidence is largely animal. None of the four has been tested against lifespan.

Exercise is the most potent lever, and the two intensities work differently. Steady, conversational-pace aerobic work — zone 2 training — is the strongest stimulus for building more mitochondria, because accumulated volume at low intensity is what flips the biogenesis switch.^[17] High-intensity intervals work through a different, rapid energy-stress pathway and preferentially improve mitochondrial quality and fitness (VO₂ max, one of the strongest predictors of mortality). The catch fits the hormesis logic: the dose matters, and relentless high-intensity training without recovery can tip from adaptive stress into mitochondrial overload, so the standard prescription is mostly easy volume with a smaller dose of hard intervals.^[18]

Fasting and caloric restriction switch on the cleanup crew. When energy runs low, the cell's low-fuel sensor activates and drives mitophagy — the selective clearing of damaged mitochondria — while restraining the growth pathway — mTOR, the mechanistic target of rapamycin — that suppresses it.^[19] This is part of why time-restricted eating and fasting show metabolic benefits beyond simple calorie reduction, and it is the same machinery described under deregulated nutrient sensing.

Heat and cold both qualify as hormesis. Sauna heat denatures proteins just enough to trigger the heat-shock response, which deploys protective chaperone proteins that protect mitochondrial membranes — one mechanism proposed for the observational mortality association with frequent sauna use. Cold exposure drives the opposite stimulus: it activates brown fat and the uncoupling machinery that burns fuel for heat, pushing fresh mitochondrial biogenesis^[20] — though whether brief cold-plunge protocols sustain this in humans is unsettled, and most of the metabolic evidence comes from prolonged mild-cold air exposure rather than ice baths.

Sleep and circadian alignment protect the machinery. Mitochondrial energy output and antioxidant defences are synchronised to the 24-hour clock, so disrupted or insufficient sleep degrades mitochondrial gene expression and raises oxidative stress.^[21][22] Melatonin — produced not only by the pineal gland but inside mitochondria themselves — acts there as a built-in antioxidant, which is part of why consistent, dark-aligned sleep is genuine mitochondrial maintenance.^[23]

The supplement landscape

Weak. Every compound here is mechanism-rich and outcome-poor, and every one that has been through a proper randomised trial missed its primary endpoint. The site covers the pharmacology in depth under geroprotectors.

• Urolithin A has the most human data of the group, and it is more equivocal than its marketing. It is a postbiotic — a compound gut bacteria make from pomegranate and berry precursors, though only about 30–40% of people carry the microbes to produce useful amounts — and it directly stimulates mitophagy. Two randomised trials pull in different directions. ATLAS, in 88 overweight middle-aged adults over four months, found about 12% more muscle strength than placebo and lower C-reactive protein (a general marker of inflammation), with clinically meaningful gains in aerobic endurance and walking distance — but missed its primary endpoint of peak power output, and every author was affiliated with the company that makes the product tested.^[24] A second trial in 66 adults aged 65–90 missed both of its primary endpoints — no improvement in six-minute walk distance or in maximal ATP production — and the muscle-endurance signal it did show at two months had gone by four months as the placebo group caught up.^[25] The two results have not been reconciled. The honest reading is a real but small strength signal in middle-aged adults, not established benefit in older ones.
• NAD⁺ precursors — nicotinamide mononucleotide and nicotinamide riboside — reliably raise blood levels of NAD⁺, a coenzyme essential to energy production and repair that declines with age. The repletion is real; the functional payoff in muscle is where the evidence is weakest. A randomised trial gave 32 adults aged 55–80 nicotinamide riboside with pterostilbene around an induced muscle injury and found no improvement in muscle stem-cell recruitment or in any measure of muscle recovery and regeneration.^[26] See deregulated nutrient sensing for what raising NAD⁺ does and doesn't buy elsewhere.
• Coenzyme Q10 is a genuine component of the energy chain and reasonable in specific deficiency or statin contexts; for healthy adults the longevity case is thin (see Coenzyme Q10).
• Rapamycin, an mTOR inhibitor, promotes mitophagy and is among the most credible pharmacological geroprotectors, but only at low, intermittent doses that spare its metabolic side effects.^[27] Its one randomised trial in healthy adults missed its primary endpoint too (geroprotectors). Firmly investigational, not a routine intervention.

The honest ranking: urolithin A has a modest strength signal in one trial and a null in another, the NAD⁺ precursors raise a meaningful molecule without yet proving they do anything useful in muscle, and the rest is mechanism in search of outcomes. All of it sits well behind the hormetic levers above.

A caution on mouse data: the thermoneutrality gap

Methodological caveat, not a harm signal: a standing reason to discount striking mitochondrial metabolic results in mice — but not a blanket dismissal of mouse work, as the counterweight below shows.

One reason to be sceptical of dramatic mitochondrial claims is that most of the underlying biology comes from laboratory mice — and standard mouse housing quietly distorts exactly this system. Labs keep mice at around 22 °C for human comfort, but that is well below a mouse's comfort zone (about 30 °C), so caged mice live under constant mild cold stress, burning a third of their energy just staying warm.^[28] Because cold is itself a mitochondrial stimulus, standard housing chronically revs their metabolism in ways that don't match a thermally comfortable human — shifting baseline glucose handling and brown-fat activity enough that moving long-lived mutant mice to thermoneutrality visibly changes their metabolic physiology. Tellingly, though, their longevity advantage persisted — so the gap is a reason to discount specific metabolic readouts, not to throw out the lifespan findings.^[29] It is a concrete example of why a striking mitochondrial result in cold-stressed mice may not carry over to people, and why the human-trial evidence is what deserves the weight.

What this does and doesn't tell you

What it tells you: mitochondrial dysfunction is a real, integrative driver of aging — it links energy decline to inflammation (through the cGAS-STING DNA alarm) and to the post-viral fatigue syndromes, and, on observational evidence only, it tracks with frailty and dementia through the muscle–brain axis. Most importantly, mitohormesis explains why the familiar levers work: exercise, fasting, heat, and cold are effective precisely because they are controlled doses of mitochondrial stress that trigger renewal. This is one of the few hallmarks where the human intervention evidence is more than mechanism — though still on surrogate measures, never on lifespan.

What it doesn't tell you: that any supplement reliably extends human life by "boosting" mitochondria — every compound tested in a proper randomised trial, urolithin A and an NAD⁺ precursor and rapamycin alike, missed its primary endpoint. Nor that more antioxidants are better; taken in large isolated doses around training they can blunt the adaptation. Nor that the dramatic mouse results will translate. The durable message is the same one that runs through this site: the proven way to keep your mitochondria young is to use them, rest them, and stress them in the right doses.

Further reading

• Srivastava S. The mitochondrial basis of aging and age-related disorders. Genes (Basel) 2017.^[30]
• Wei X, et al. Mitochondrial dysfunction and aging: multidimensional mechanisms and therapeutic strategies. Biogerontology 2025.^[31]
• Gorgori-Gonzalez A, et al. Leveraging mitochondrial stress to improve healthy aging. Sports Med Health Sci 2026.^[32]
• Ding P, et al. Mitochondrial DNA leakage triggers inflammation in age-related cardiovascular diseases. Front Cell Dev Biol 2024.^[33]
• Salminen A, Kaarniranta K, Kauppinen A. Activation of cGAS-STING signaling in senescent cells promotes the aging process by remodeling the functions of the immune system. Biogerontology 2025.^[34]
• Tian Q, et al. Skeletal muscle mitochondrial function predicts cognitive impairment and is associated with biomarkers of Alzheimer's disease and neurodegeneration. Alzheimers Dement 2023 — Baltimore Longitudinal Study of Aging.^[35]
• Wang P, et al. WASF3 disrupts mitochondrial respiration and may mediate exercise intolerance in myalgic encephalomyelitis/chronic fatigue syndrome. Proc Natl Acad Sci U S A 2023.^[36]
• Singh A, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Rep Med 2022 — ATLAS; missed its primary endpoint; manufacturer-authored.^[37]
• Liu S, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults. JAMA Netw Open 2022 — missed both primary endpoints.^[38]
• Jensen JB, et al. A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals. JCI Insight 2022.^[39]
• James CM, et al. How murine models of human disease and immunity are influenced by housing temperature and mild thermal stress. Temperature (Austin) 2023.^[40]

---